**Core Concept:** Antineoplastic agents are drugs that inhibit or prevent the growth and division of cancer cells by targeting cellular processes involved in cell cycle regulation, DNA synthesis, and protein synthesis. Hodgkin's lymphoma, non-Hodgkin's lymphoma, and small cell carcinoma of the lung are types of cancer that originate from lymphocytes, B cells, or small airways respectively.

**Why the Correct Answer is Right:** Methotrexate (Drug A) is an antineoplastic agent used in the management of these cancers due to its ability to inhibit dihydrofolate reductase (DHFR), a key enzyme involved in purine and pyrimidine synthesis. By inhibiting DHFR, methotrexate interferes with DNA and RNA synthesis, leading to cell cycle arrest and death of rapidly dividing cancer cells.

**Why Each Wrong Option is Incorrect:**

A. Cyclophosphamide (Drug C) is a cytotoxic agent used in the treatment of various cancers, including lymphomas and solid tumors. However, it is not specific to Hodgkin's lymphoma, non-Hodgkin's lymphoma, or small cell carcinoma of the lung. Cyclophosphamide targets DNA synthesis but its mechanism is broader and does not specifically target the mentioned cancers.

B. Vinblastine (Drug B) is a microtubule inhibitor used in the treatment of various malignancies. It is effective against lymphomas, but not specifically for Hodgkin's lymphoma, non-Hodgkin's lymphoma, or small cell carcinoma of the lung. Vinblastine's mechanism involves inhibiting microtubule assembly, which affects cell division and migration in various cancers. However, it is not specific to the mentioned cancers.

C. Thalidomide (Drug D) is a sedative-hypnotic drug that can be used in the treatment of certain cancers, including lymphomas and multiple myeloma. However, thalidomide is not specific to Hodgkin's lymphoma, non-Hodgkin's lymphoma, or small cell carcinoma of the lung. Thalidomide's mechanism involves immunomodulation and anti-angiogenic properties, which are not specific to the mentioned cancers.

**Clinical Pearl:** In the treatment of lymphomas, the choice of antineoplastic agents depends on the type and stage of the disease, the patient's age, comorbidities, and the presence of specific genetic mutations. A tailored approach ensures optimal treatment outcomes while minimizing potential side effects.